Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Overall, I am encouraged by the decisions management is making and am optimistic about Lilly's long-term prospects. Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback